Logo

Detection of HCV-Specific IFN-? Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users

Author(s):
Jacqueline K FlynnJacqueline K Flynn2,*, Rachel Sacks-DavisRachel Sacks-Davis4, Peter HiggsPeter Higgs5, Campbell AitkenCampbell Aitken4, Sarah MoneerSarah Moneer6, Vijay SuppiahVijay Suppiah8, Lilly TracyLilly Tracy9, Rosemary FfrenchRosemary Ffrench10, Scott BowdenScott Bowden9, Heidi DrummerHeidi Drummer11, Jacob GeorgeJacob George7, Mandvi BharadwajMandvi Bharadwaj6, Margaret HellardMargaret Hellard4
2Department of Infectious Diseases, Monash University, Melbourne, Australia
4Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
5National Drug Research Institute, Faculty of Health Sciences, Curtin University, Melbourne, Australia
6Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia
8School of Pharmacy, University of South Australia, Adelaide, Australia
9Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
10Department of Immunology, Monash University, Melbourne, Australia
11Department of Microbiology, Monash University, Clayton, Australia
7Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Sydney, Australia


Hepatitis Monthly:Vol. 14, issue 1; 14678
Published online:Jan 07, 2014
Article type:Research Article
Received:Sep 15, 2013
Accepted:Nov 20, 2013
How to Cite:Jacqueline K FlynnRachel Sacks-DavisPeter HiggsCampbell AitkenSarah MoneerVijay SuppiahLilly TracyRosemary FfrenchScott BowdenHeidi DrummerJacob GeorgeMandvi BharadwajMargaret Hellardet al.Detection of HCV-Specific IFN-? Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users.Hepat Mon.14(1):14678.https://doi.org/10.5812/hepatmon.14678.

Abstract

Background:

Detectable HCV-specific cellular immune responses in HCV antibody and RNA negative people who inject drugs (PWID) raise the question of whether some are resistant to HCV infection. Immune responses from people who have been exposed to hepatitis C virus (HCV) and remain anti-HCV negative are of interest for HCV vaccine development; however, limited research addresses this area.

Objectives:

In a cohort of HCV antibody and RNA negative PWID, we assessed whether the presence of HCV-specific IFN-? responses or genetic associations provide any evidence of protection from HCV infection.

Patients and Methods:

One hundred and ninety-eight participants were examined longitudinally for clinical, behavioral, social, environmental and genetic characteristics (IFNL3 genotype [formally IL-28B] and HLA type). Sixty-one of the 198 participants were HCV antibody and RNA negative, with 53 able to be examined longitudinally for HCV-specific IFN-? ELISpot T cell responses.

Results:

Ten of the 53 HCV antibody and RNA negative participants had detectable HCV-specific IFN-? responses at baseline (18%). The magnitude of IFN-? responses averaged 131 +/- 96 SFC/106 PBMC and the breadth was mean 1 +/- 1 pool positive. The specificity of responses were mainly directed to E2, NS4b and NS5b. Participants with (10) and without (43) HCV-specific IFN-? responses did not differ in behavioral, clinical or genetic characteristics (P > 0.05). There was a larger proportion sharing needles (with 70%, without 49%, P = 0.320) and a higher incidence of HCV (with 35.1 per 100 py, 95% CI 14.6, 84.4, without 16.0 per 100 py, 95% CI 7.2, 35.6, P = 0.212) in those with IFN-? responses, although not statistically significant. Half the participants with baseline IFN-? responses became HCV RNA positive (5/10), with one of these participants spontaneously clearing HCV. The spontaneous clearer had high magnitude and broad Th1 responses, favorable IFNL3 genotype and favorable HLA types.

Conclusions:

This study demonstrated the detection of HCV-specific IFN-? responses in HCV antibody and RNA negative individuals, with a tendency for HCV-specific IFN-? responses to be associated with HCV exposure. The potential role of HCV-specific IFN-? responses in those who remained HCV RNA negative is of value for the development of novel HCV therapeutics.

Full Text

Full text is available in PDF

comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles